VIDEO: Acellular implant may improve outcomes in patients with early arthritis
Click Here to Manage Email Alerts
Key takeaways:
- The acellular implant group had statistically significant improvements in overall outcome scores and subscores.
- The acellular implant should not be used in patients with Kellgren-Lawrence grade 4.
NEW ORLEANS — Use of an acellular implant made of aragonite may improve outcomes in patients with early arthritis compared with debridement or microfracture, according to results presented at the Biologic Association Annual Summit.
Kenneth R. Zaslav, MD, and colleagues randomly assigned 250 patients with articular cartilage and osteochondral defects and a Kellgren-Lawrence (KL) grade of 0, 2 or 3 to receive either an acellular implant made of aragonite (Agili-C, CartiHeal) or standard of care, including debridement and microfracture. During a 24-month period, researchers found a retention rate of 98%. Zaslav said the acellular implant group had statistically significant improvements in KOOS overall scores and subscores.
“We are happy to show clear superiority for this [implant], whether we use it in small lesions, large lesions greater than 3 cm, KL grade 0 or normal X-rays, or KL grade 2 or 3 with significant arthritis,” Zaslav, director of the Center for Regenerative Orthopedic Medicine at Lenox Hill Hospital-Northwell Health, told Healio. “There were good results in all of those patients with this new acellular, off-the-shelf implant that is less expensive than all the other options available at this time.”
Collapse
Zaslav KR. Use of augmentation and scaffolds in cartilage defects of the knee. Presented at: Biologic Association Annual Summit; May 6-7, 2023; New Orleans.
Read more about
Click Here to Manage Email Alerts